Abstract: Computer implemented method for selecting functional biomarkers to identify a target condition in a subject, the method comprising the steps of: obtaining groups of equivalent physiological signals generated during a stimulation, comprising a first group of physiological signals from subjects presenting the target condition, and a second group of physiological signals from subjects of control condition, not presenting the target condition; identifying at least one frequency sub-band for each group of physiological signals; obtaining per of the at least one identified frequency sub-band at least a corresponding pattern; and selecting the one or more patterns having similarity values to the physiological signals of each group that differentiate the groups of physiological signals as functional biomarkers. The functional biomarkers may be used for training a classifier for identifying the target condition in a subject.

Abstract: A method for obtaining a near-infrared spectroscopy (fNIRS) cerebral signal in a subject includes: placing a near-infrared emitter and respective proximal and distal near-infrared detectors on a skin of a head of a subject; during a baseline recording stage with the subject in resting-state, record near-infrared signals, the recorded signals including a baseline deep-signal and a baseline shallow-signal; calculate a scaling factor between amplitudes of the baseline deep-signal and the baseline shallow-signal at a given task-frequency; with the subject undergoing a cyclic cerebral stimulation at the task-frequency during a stimulation recording stage, record near-infrared signals, the recorded signals comprising a shallow-signal and a deep-signal; and applying the scaling factor to the shallow-signal, calculating the cerebral signal at the task-frequency as a difference between the deep-signal and the scaled shallow-signal, at the task-frequency.

Abstract: Procedure for the generation of a reflex tear secretion, which comprises the chemical stimulation of the cornea of the eye of a subject by applying a controlled jet of a gas with a high CO2 content, of at least 80% of CO2. Compact device (1,1?) for the generation of a reflex tear secretion, comprising a gas source (7) in the form of a disposable type cartridge containing a pressurized gas with a composition of at least 80% of CO2; and a pneumatic circuit connecting an outlet mouth of said gas source (7) with a gas outlet nozzle (3) of the device (1,1?), the circuit comprising pressure regulation means (8) and flow rate (17) regulation means suitable for ejecting puffs of gas through the outlet nozzle (3) at a predetermined pressure and flow rates.

Abstract: A method for obtaining a near-infrared spectroscopy (fNIRS) cerebral signal in a subject includes: placing a near-infrared emitter and respective proximal and distal near-infrared detectors on a skin of a head of a subject; during a baseline recording stage with the subject in resting-state, record near-infrared signals, the recorded signals including a baseline deep-signal and a baseline shallow-signal; calculate a scaling factor between amplitudes of the baseline deep-signal and the baseline shallow-signal at a given task-frequency; with the subject undergoing a cyclic cerebral stimulation at the task-frequency during a stimulation recording stage, record near-infrared signals, the recorded signals comprising a shallow-signal and a deep-signal; and applying the scaling factor to the shallow-signal, calculating the cerebral signal at the task-frequency as a difference between the deep-signal and the scaled shallow-signal, at the task-frequency.

Abstract: An interchangeable sensor device for a functional near-infrared spectroscopy system (fNIRS) is a non-invasive device intended to detect changes in the concentration of hemoglobin species on any body surface area. The device includes a plurality of measurement units having different elastic configurations, each intended to be adapted to a specific area of the body, and a control unit for controlling any of the measurement units. Each of the measurement units is equipped with a first connector and the control unit is equipped with a second connector, which connectors allow the control unit to be interchangeably connected to any of the measurement units.

Abstract: The invention relates to compounds having formula (I) wherein A is selected from the group consisting of: a) optionally substituted (C1-C8) alkyl; b) optionally substituted (C3-C6) cycloalkyl; c) optionally substituted (C6-C14) aryl; d) optionally substituted (C6-C14) heteroaryl; e) C(O)—(C6-C14) aryl, in which group (C6-C14) aryl is optionally substituted; f) C(O)—(C6-C14) heteroaryl, in which group (C6-C14) heteroaryl is optionally substituted; g) CH(OH)—(C6-C14) aryl, in which group (C6-C14) aryl is optionally substituted; and h) CH(OH)—(C6-C14) heteroaryl, in which group (C6-C14) heteroaryl is optionally substituted. The invention also relates to methods for the production of said compounds, to pharmaceutical and veterinary compositions comprising said compounds and to the therapeutic uses thereof, such as for the prevention and/or treatment of dry eye syndrome, vaginal dryness and/or burning mouth syndrome.

Abstract: The invention relates to an interchangeable sensor device (1) for a functional near-infrared spectroscopy system (fNIRS) which is a non-invasive device intended to detect changes in the concentration of haemoglobin species on any body surface area. The device comprises a plurality of measurement units (200) having different elastic configurations, each intended to be adapted to a specific area of the body, and a control unit (300) for controlling any of the measurement units (200). Each of the measurement units (200) is equipped with a first connector (212) and the control unit (300) is equipped with a second connector (312), which connectors allow the control unit (300) to be interchangeably connected to any of live measurement units (200).

Abstract: The invention relates to compounds having formula (I) wherein A is selected from the group consisting of: a) optionally substituted (C1-C8) alkyl; b) optionally substituted (C3-C6) cycloalkyl; c) optionally substituted (C6-C14) aryl; d) optionally substituted (C6-C14) heteroaryl; e) C(O)—(C6-C14) aryl, in which group (C6-C14) aryl is optionally substituted; f) C(O)—(C6-C14) heteroaryl, in which group (C6-C14) heteroaryl is optionally substituted; g) CH(OH)—(C6-C14) aryl, in which group (C6-C14) aryl is optionally substituted; and h) CH(OH)—(C6-C14) heteroaryl, in which group (C6-C14) heteroaryl is optionally substituted. The invention also relates to methods for the production of said compounds, to pharmaceutical and veterinary compositions comprising said compounds and to the therapeutic uses thereof, such as for the prevention and/or treatment of dry eye syndrome, vaginal dryness and/or burning mouth syndrome.

Abstract: The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.

Abstract: The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.

Abstract: The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.

Abstract: The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.

Abstract: The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.

Abstract: The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.

Abstract: The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.

Abstract: The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.

Abstract: The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.

Abstract: The invention relates to compounds having formula (I), which can block the response to chemical substances or thermal stimuli or mediators of inflammation of nociceptors, a production method thereof and compositions containing same.

Abstract: The invention relates to the use of a calcium channel blocking agent for the manufacture of a medicament for alleviatirtg pain, such as ocular pain. Particular calcium channel blocking agents that can be used in accordance with the invention are diltiazem, verapamil, nifedipine, nicardipine, and nimodipine.